908 Devices (NASDAQ:MASS) Stock Crosses Below 50 Day Moving Average – What’s Next?

908 Devices Inc. (NASDAQ:MASS) passed below its 50-day moving average during trading on Tuesday. The stock has a 50-day moving average of $11.19 and traded as low as $9.82. 908 Devices shares last traded at $9.98, with a volume of 898,536 shares changing hands.

908 Devices News Roundup

Here are the key news stories impacting 908 Devices this week:

• Positive Sentiment: Third-quarter revenue rose 35% year over year to a record $19 million, driven by the FTIR portfolio, and device shipments reached a company record. Revenue exceeded analyst estimates of $18.31 million. 908 Devices Q3 2026 results
• Positive Sentiment: The quarterly loss of $0.11 per share was narrower than the $0.15–$0.16 loss expected by analysts. 908 Devices Q3 earnings report
• Neutral Sentiment: 2026 revenue guidance is $68.5 million–$70.0 million, with the midpoint roughly in line with the $69.1 million analyst consensus—solid visibility, but not an obvious forecast beat. 908 Devices Q3 2026 results
• Negative Sentiment: The company remains loss-making, which may temper the upbeat revenue and shipment figures. The reported short-interest entry lists zero shares and zero days to cover despite describing a significant increase, so it appears inconsistent and offers little reliable signal. 908 Devices earnings information

Analyst Ratings Changes

A number of equities analysts recently issued reports on MASS shares. Wall Street Zen cut 908 Devices from a “buy” rating to a “hold” rating in a report on Saturday, September 12th. Canaccord Genuity Group initiated coverage on 908 Devices in a report on Thursday, September 10th. They set a “buy” rating and a $13.50 target price for the company. Roth Capital increased their price target on 908 Devices from $11.00 to $13.00 and gave the company a “buy” rating in a research report on Wednesday, August 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of 908 Devices in a research report on Wednesday, November 4th. Finally, Stifel Nicolaus lifted their price target on 908 Devices from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $12.83.

908 Devices Trading Down 13.3%

The stock has a market cap of $412.47 million, a P/E ratio of -10.51 and a beta of 0.66. The firm’s fifty day moving average is $11.19 and its 200 day moving average is $8.51.

908 Devices (NASDAQ:MASS) last released its earnings results on Tuesday, November 10th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.04. The firm had revenue of $18.95 million during the quarter, compared to analyst estimates of $18.31 million. 908 Devices had a negative net margin of 56.96% and a negative return on equity of 12.54%. Research analysts forecast that 908 Devices Inc. will post -0.59 earnings per share for the current fiscal year.

Insider Buying and Selling

In other 908 Devices news, SVP John Kenneweg sold 21,399 shares of the firm’s stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $10.11, for a total value of $216,343.89. Following the sale, the senior vice president owned 57,784 shares of the company’s stock, valued at $584,196.24. This trade represents a 27.02% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Christopher Brown sold 30,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an average price of $10.95, for a total value of $328,500.00. Following the completion of the sale, the director directly owned 775,559 shares in the company, valued at $8,492,371.05. This trade represents a 3.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 134,115 shares of company stock valued at $1,473,296. Insiders own 28.20% of the company’s stock.

Institutional Investors Weigh In On 908 Devices

Hedge funds have recently modified their holdings of the business. Legal & General Group Plc acquired a new stake in shares of 908 Devices in the second quarter worth $27,000. Allworth Financial LP bought a new position in 908 Devices during the second quarter worth $29,000. Renaissance Technologies LLC increased its position in 908 Devices by 3.6% during the first quarter. Renaissance Technologies LLC now owns 230,200 shares of the company’s stock worth $1,409,000 after acquiring an additional 8,100 shares during the period. Pier 88 Investment Partners LLC raised its stake in 908 Devices by 59.2% during the 3rd quarter. Pier 88 Investment Partners LLC now owns 22,600 shares of the company’s stock valued at $279,000 after purchasing an additional 8,400 shares during the last quarter. Finally, Intelligence Driven Advisers LLC acquired a new position in 908 Devices during the 1st quarter valued at $61,000. 88.06% of the stock is owned by institutional investors.

About 908 Devices

908 Devices Inc. is a Boston-based analytical technology company that develops purpose-built mass spectrometers for use outside traditional laboratory environments. Its instruments are designed to provide rapid chemical and biological analysis in the field, helping users identify unknown substances and make time-sensitive decisions. The company’s product portfolio includes the MX908 handheld mass spectrometer, which is used to detect and identify chemical threats, explosives, narcotics and other hazardous materials.